Trial Profile
A Phase I Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Nelfinavir (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 08 Feb 2018 New trial record